Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly | Mexico | Healthcare | Pharmaceuticals | MX$14.44T | 68.3x | 0.72 | MX$16,109.70 | -2.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
J&J | Mexico | Healthcare | Pharmaceuticals | MX$7.88T | 27.9x | -0.49 | MX$3,278 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AbbVie | Mexico | Healthcare | Pharmaceuticals | MX$7.50T | 88.4x | -7.36 | MX$4,343.48 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novo Nordisk | Mexico | Healthcare | Pharmaceuticals | MX$6.84T | 23.3x | 1.22 | MX$1,525.21 | 1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Roche Holding Participation | Mexico | Healthcare | Pharmaceuticals | MX$5.82T | 31x | -1.05 | MX$6,873.87 | -3.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merck&Co | Mexico | Healthcare | Pharmaceuticals | MX$4.81T | 14x | 0 | MX$1,901.19 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Astrazeneca DRC | Mexico | Healthcare | Pharmaceuticals | MX$4.79T | 33.8x | 1.88 | MX$1,510 | -0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novartis | Mexico | Healthcare | Pharmaceuticals | MX$4.58T | 19.4x | -1.08 | MX$2,027 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Amgen | Mexico | Healthcare | Pharmaceuticals | MX$3.37T | 41.1x | -1.08 | MX$6,430 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Pfizer | Mexico | Healthcare | Pharmaceuticals | MX$2.92T | 18.1x | 0.07 | MX$514 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sanofi | Mexico | Healthcare | Pharmaceuticals | MX$2.90T | 23.9x | 8.51 | MX$1,162 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Gilead Sciences | Mexico | Healthcare | Pharmaceuticals | MX$2.84T | 296.1x | -3.28 | MX$2,313 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bristol-Myers Squibb | Mexico | Healthcare | Pharmaceuticals | MX$2.45T | -13.7x | 0.06 | MX$1,215.50 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
McKesson | Mexico | Healthcare | Pharmaceuticals | MX$1.63T | 29.6x | -22.68 | MX$11,995.68 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
GSK plc DRC | Mexico | Healthcare | Pharmaceuticals | MX$1.59T | 23.7x | -0.51 | MX$767 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bayer | Mexico | Healthcare | Pharmaceuticals | MX$490.55B | -8.8x | -0.71 | MX$516.89 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Teva DRC | Mexico | Healthcare | Pharmaceuticals | MX$379.15B | -11.4x | 0.06 | MX$327.50 | -0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Grifols Pref | Mexico | Healthcare | Pharmaceuticals | MX$140.21B | 45x | 0.17 | MX$126.63 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bausch Health | Mexico | Healthcare | Pharmaceuticals | MX$53.24B | -57.6x | -0.61 | MX$151 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genomma Lab Int | Mexico | Healthcare | Pharmaceuticals | MX$23.69B | 11.1x | 0.12 | MX$23.70 | -1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24.3% Upside | Upgrade to Pro+ |